Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Matinas BioPharma Holdings, Inc. filings document a clinical-stage biopharmaceutical issuer built around lipid nanocrystal delivery technology and MAT2203, its oral amphotericin B antifungal candidate. Regulatory disclosures include material-event reports, proxy matters, governance changes, capital-structure actions, and public-company compliance items.
Recent MTNB filings cover NYSE American continued-listing notices, board and officer changes, executive compensation arrangements, warrant exchanges, authorized-share amendments, stockholder meeting results, and equity incentive plan approvals. These records also disclose the company’s common-stock structure, voting matters, risk-related listing issues, and formal reporting obligations as a public biotechnology company.
Matinas BioPharma Holdings, Inc. has received another notice from NYSE American that it is not meeting continued listing standards tied to stockholders’ equity. The exchange cited Section 1003(a)(ii), which requires at least $4.0 million in equity when a company has losses in three of its four most recent fiscal years, while Matinas reported stockholders’ equity of $3.022 million as of March 31, 2026 and losses in five recent fiscal years.
The company had previously been notified that it also failed Section 1003(a)(iii), which requires at least $6.0 million in equity after losses in five consecutive years, with equity of $4.83 million as of December 31, 2025. NYSE American has accepted Matinas’ compliance plan and granted a plan period through October 2, 2027, during which the stock will remain listed on NYSE American under the symbol MTNB, subject to ongoing review and satisfaction of other listing requirements.
Matinas Biopharma Holdings, Inc. files a prospectus supplement updating the list of selling stockholders for a previously registered resale of 16,894,212 shares of Common Stock. The registered shares consist of 5,631,404 shares issuable upon conversion of Series C Convertible Preferred Stock and 11,262,808 shares issuable upon exercise of Warrants. The supplement reports pro rata distributions and assignments of Preferred Stock and Warrants by Sanitam Partners LLC and Platinum Point Capital LLC to underlying holders and an employee benefit plan. The resale registration covers shares held by listed selling stockholders; the prospectus states the company will not receive proceeds from resales by the selling stockholders. Shares outstanding were 6,406,191 as of June 22, 2026. The supplement also discloses a last reported sale price of $0.60 on June 18, 2026.
Matinas BioPharma Holdings, Inc. filed a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights or units. The shelf permits multiple offerings in one or more tranches; proceeds are intended for working capital and general corporate purposes.
As of June 16, 2026, 6,406,191 shares of common stock were issued and outstanding. The prospectus discloses a public float of $5,579,577 (based on 6,398,597 shares held by non-affiliates as of June 1, 2026) and states the last reported sales price was $0.75 per share on June 15, 2026.
Matinas BioPharma Holdings, Inc. reported a Q1 2026 net loss of $1.9M, similar to the prior year, with cash and cash equivalents of $2.4M and total assets of $5.9M. Stockholders’ equity fell to $3.0M, down from $6.3M a year earlier.
The company, a clinical-stage biopharma built around its lipid nanocrystal (LNC) delivery platform and lead asset MAT2203, cut research and development spending to zero in the quarter while general and administrative costs stayed around $1.9M. Management discloses substantial doubt about its ability to continue as a going concern.
Matinas is seeking to monetize MAT2203 through a license, sale or partnership and may use its At-The-Market Sales Agreement with BTIG, but capacity is capped by Form S-3 public float limits. The NYSE American has notified the company that it is below stockholders’ equity listing standards, and Matinas has submitted a compliance plan.
Matinas BioPharma Holdings, Inc. reported that it received a notice from NYSE American on April 2, 2026 stating it is not in compliance with the exchange’s continued listing standards because of low stockholders’ equity and multi-year losses.
As of December 31, 2025, stockholders’ equity was $4.83 million and the company reported losses in each of the most recent five fiscal years, below the $6.0 million equity requirement for issuers with five years of losses. Matinas has until May 2, 2026 to submit a plan and may have up to an 18‑month cure period if the plan is accepted. The company’s shares remain listed for now, but delisting proceedings could begin if NYSE American does not accept the plan or if compliance is not regained. The company also highlighted that its auditor’s report on the 2025 financial statements includes an explanatory paragraph raising substantial doubt about its ability to continue as a going concern.
Matinas BioPharma Holdings, Inc. files its annual report detailing a pivot from internal R&D toward partnering or monetizing its lead antifungal candidate MAT2203, built on its lipid nanocrystal platform. A terminated licensing negotiation in October 2024 led to an 80% workforce reduction, a pause of further clinical development and evaluation of strategic alternatives, including a potential asset sale or Company winddown.
To extend its cash runway, Matinas completed an April 2024 equity offering of 666,667 common shares and warrants for about $10 million, and a February–April 2025 preferred stock and warrant financing for $3.3 million. The company executed a 1‑for‑50 reverse stock split and later increased authorized common shares back to 500,000,000, enabling significant potential future issuance, including up to 16,894,212 shares tied to the preferred stock and 2025 warrants.
MAT2203 has FDA Fast Track, Qualified Infectious Disease Product and Orphan Drug designations, and Phase 2 data in cryptococcal meningitis show strong early fungicidal activity, high survival and markedly lower kidney toxicity than IV amphotericin B. However, progression to the FDA‑aligned Phase 3 ORALTO trial in invasive aspergillosis depends on securing a partner or additional capital, and there is no assurance a transaction will occur.
Matinas BioPharma Holdings, Inc. reported a leadership change in its finance function. Following the previously announced resignation of Chief Financial Officer Keith Kucinski effective January 17, 2026, the board appointed Jerome D. Jabbour, the company’s Chairman, President and Chief Executive Officer, as interim Chief Financial Officer effective January 22, 2026.
Jabbour, 51, is a co‑founder of the company and has held senior roles since 2013, including Chief Executive Officer since March 2018 and Chairman of the Board since March 2025. He will also serve as the company’s principal financial officer and principal accounting officer until a successor is appointed or he resigns or is removed. His existing compensation arrangements remain unchanged, and the company states there are no special appointment arrangements, family relationships, or related‑party transactions connected to this role.
Matinas BioPharma Holdings updated the employment agreement of its Chief Executive Officer, Jerome D. Jabbour, through a third amendment. The change extends the deadline for a qualifying Change in Control that would trigger his retention bonus from March 31, 2026 to June 30, 2026. The retention bonus remains the greater of his target annual bonus for the year of the Change in Control or $299,000.
The amendment also splits the retention bonus into two stages: two-thirds payable when Matinas signs a definitive agreement that would result in a Change in Control, and one-third payable immediately before closing, provided he has not resigned without Good Reason or been terminated for Cause. If he resigns for Good Reason or is terminated other than for Cause, the retention bonus becomes payable within ten days and no later than immediately before a Change in Control. Jabbour is guaranteed an annual bonus for 2025 of at least his target bonus, payable by February 1, 2026, and the definitions of Change in Control, Cause, and Good Reason are updated, including adding transactions that materially change the company’s primary business.
Matinas BioPharma Holdings, Inc. reported a planned leadership change. On November 18, 2025, Chief Financial Officer Keith Kucinski informed the company that he intends to resign from his role, effective January 17, 2026, to pursue other opportunities. The company stated that his decision is not due to any disagreement regarding its operations, policies, or practices, indicating an orderly transition rather than a dispute-driven departure.
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock. The filing shows 0 shares beneficially owned with 0 sole or shared voting and dispositive power.
The date of event triggering the filing is 09/30/2025. Highbridge certifies the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.